Efficacy of Endovascular Thrombectomy in the Oldest Old (Stroke 90+ Study): A Community Center Experience

INTRODUCTION

Acute ischemic stroke is a leading cause of death and disability in United States affecting approximately 795,000 people each year [1]. Sudden-onset of weakness in an extremity or face, difficulty expressive or receptive aphasia, visual loss, confusion, and acute loss of balance or coordination are classic symptoms. Timely treatment of ischemic but not yet nonviable brain cells can prevent death and limits disability.

Over the past 20 years, intravenous thrombolysis (IVT) as proven treatment of acute ischemic stroke effects improvement in a relatively small percentage of strokes, ones mostly due to small vessel occlusions. Large vessel occlusions (LVOs) with their large clot burden are recalcitrant to IVT with suboptimal recanalization [2]. In fact, the implementation of IVT has been low internationally [3-5]. A recent series of well-designed and well-conducted randomized controlled trials (RCT) showed improved outcomes for LVOs in patients treated with endovascular thrombectomy (EVT) [6].

While EVT is considered as the most effective treatment for properly selected patients with acute ischemic stroke and large vessel occlusion by a recent editorial reviewed [6], its efficacy and appropriateness in older patients is still debated, as many studies have excluded patients over 80 years or included a much smaller sample size of such patients in the study. The landmark HERMES collaborative trial (Highly Effective Reperfusion Evaluated in Multiple Endovascular Stroke Trials), and its sub-study suggest not withholding EVT on the basis of age alone [7,8] although surveyed clinicians state that age still plays a key role when making individual thrombectomy decisions [9]. In addition, the most recent guidelines from the American Stroke Association/American Heart Association suggest more studies are needed for patients >=90 years especially in the “real-world setting” [10].

Therefore, we report “real world” outcomes of EVT in acute ischemic stroke patients 90 and older at the time of EVT. Our community hospital experience provides a demonstration of whether older patients may benefit from various stroke treatments outside an academic medical center setting. For this study, IRB exemption status approval was obtained from WCG IRB.

METHODS

RESULTS

Table 1 shows sample characteristics. Among total 31 patients, average age was 92.9 +/-2.4 (min 90 and max 98). Twenty (65%) were female. Twenty-five (81%) were Caucasian and 5 (16%) Asian. Of all 31 patients, 25 (80.6%) had TICI scale 0 or 1 (no or minimum perfusion) at admission. After EVT, all patients had improvement in TICI scale (Table 1). Eleven patients received IV tPA treatment as well. One patient had a small symptomatic intracranial hemorrhage (SICH) a day after EVT not related to the procedure, and three patients expired prior to their discharge.

Of remaining 28, four expired, six went into hospice care, and four lost to follow-up by 30-days post DC. Of six hospice cases, one expired by 90-day post DC, and additional three were lost to follow-up. Thus, among patients with available data, 20/27 (74%) survived to 30 days and 16/24 (67%) to 90 days.

Figure 1 compares the number of patients in each NIHSS symptomatic category at admission vs post-DC. Three patients who expired prior to DC were excluded. For their symptomatic categories, 15/28 (54%) patients improved, 10/28 (36%) remained the same, and 3/28 (11%) declined.

• Download figure
• Open in new tab

Figure 1. Number of Patients per NIH Stroke Scale at Admission vs. Post-DC

Table 2 shows the number of patients in each mRS at DC, 30- and 90-days post DC. By 30-days post DC, data were available for total 24 patients, among which 4 expired and 6 went into hospice care. Of those 10, seven were severe disabled stage (mRS 5) at DC. By 90-days post DC, data were available for total 21 patients, among which 5 expired and 5 remained at hospice care.

Figure 2 shows changes in mRS at 30- and 90-days post DC. At 30-days post DC, 7/24 (30%) patients showed improvement, 7/24 (30%) remained the same, and 10/24 (40%) declined. At 90-days post DC, 7/21 (33%) showed improvement from DC, 4/21 (19%) remained the same, and 10/21 (48%) declined.

• Download figure
• Open in new tab

Figure 2. Change in mRS at 30-Days vs. 90-Days Post-DC

Light blue line indicates mRS improvement, gray line no change, and dark blue decline during the course of 90-days follow up compared to DC.

Due to the small sample size, two separate approaches were taken. The first approach was creating a linear model using the following variables: age, race, BMI, the count of all risk factors, door to first pass (in minutes), IV tPA administration, and LVO locations. The second approach to the linear regressions involved the following valuables: age, race, BMI, specific risk factors (i.e., Afib, HLD, HTN), the count of all other risk factors, door to first pass (in minutes), IV tPA administration, and LVO locations. All of these coefficients reflect the predicted relationship between input variables and the outcome. However, none showed statistically significant results, indicating that the input variables did not significantly predict the outcomes in this sample.

DISCUSSION

This report has documented safety and benefit of EVT in patients who are 90 years and older in a community hospital setting, further supporting EVT in eligible advanced aged patients. Our outcomes were equivalent to, although there are few, other published studies [10].

In our cohort, there was one patient (patient ID: 1026) with a small SICH after EVT showing NIHSS decline from 6 to 17. However, his NIHSS improved to 1 at DC. This SICH is most likely related to reperfusion breakthrough as the patient had basilar thrombosis upon arrival and had 2 × 1 cm hematomas in left basal ganglia with mild mass effect on the internal capsule. The patient was also administered IV tPA per our protocol prior to EVT.

Three patients expired prior to their discharge. The first patient (ID: 1004) had LICA terminus occlusion with successful EVT outcomes. However, he had LMCA edema and brain herniation and expired 3 days after EVT. The second patient (ID: 1022) had left PICA with successful EVT with residual basilar thrombus and dissection of basilar artery. She did not wake up after EVT, remained intubated on ventilator, and expired four days later. The third patient (ID: 1031) had LMCA with successful EVT. However, he had multiple comorbidities including advanced Parkinson’s disease, and showed no neurologic improvement, continued to have aphasia and dysphagia inability to control secretions leading to aspiration pneumonia. He expired 18 days after EVT.

Among patients with available follow-up data, mortality rates were 26% and 33% at 30-days and 90-days post DC, respectively. Some published studies report mortality rate ranging from 31 to 37% for patients who are 80 years and older with EVT [11-13] although this rate is higher than those for younger patients. McDonough et al. compared mortality rate for patients >=85 years old demonstrating better mortality rate of 31% with EVT compared to 54.3% for those received standard of care [11].

In our cohort, all patients showed improvement in perfusion rate in TICI scale (Table 1). NIHSS also showed improvement with 63% reduction in mandate/severe to severe (NIHSS 16-42) stages (Figure 1). Although only 2 and 3 patients shifting its score to 0-2 at 30-days or 90-days post DC, respectively, mRS showed improvement in symptomatic categories (Figure 2) in 30% and 33% patients at 30-days and 90-days post DC, respectively, further supporting EVT in advanced aged adults.

While not the purpose of this study, a legitimate discussion regarding the cost benefit of treating LVO related acute stroke on a quality of life years (QUALY) basis can be in this advanced age population would have to include the cost of long term care for survivors, Also, LVO of distal carotid and middle cerebral artery trunks leads to mortality in the majority of patients prior to the availability of EVT [14,15], thus death impacts a cost per life year saved analysis in the oldest old.

A recent US nationwide retrospective cohort study using the Get with the Guidelines–Stroke (GWTG-Stroke) program [16] demonstrates steady increase in the use of EVT in patients aged 80 years and older from 3.3% in quarter 3 of 2012 to 20.8% in quarter 2 of 2019 in the study cohort (n = 12,768). This trend was similar for patients <80 (n = 29,654) during the same time period. However, the EVT treatment rates still remain lower than in younger patients. With more EVT outcome data especially from real-word setting, the use of EVT can be further evaluated in this cohort.

The limitation of this study is the small sample size. While this case series demonstrates favorable EVT outcome for this oldest old population, the outcome should be viewed with its small sample size in mind. However, this report warrants further studies in this cohort.